A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 909-914

  Glimelius, Bengt ^a,b   Sorbye H ^c   Balteskard, L ^d   Bystrom P ^b   Pfeiffer, P ^e   Tveit, K ^f   Heikkila R ^g   Keldsen, N ^h   Albertsson, M ⁱ   Starkhammar, H ^j   Garmo, H ^k   Berglund, A ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g STAVANGER UNIVERSITY HOSPITAL   (Norway)

^h HERNING HOSPITAL   (Denmark)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^k Regional Oncologic Center   (Sweden)

more..

Author keywords

5 fluorouracil; Chemotherapy; Colorectal cancer; Irinotecan; Randomized trial

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ARTICLE; BOLUS INJECTION; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOEMBOLISM;

EID: 43049109526     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm588     Document Type: Article

References (31)

1. L.B. Saltz J.V. Cox C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905 914
2. J.Y. Douillard D. Cunningham A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047
3. A. de Gramont A. Figer M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
4. L.B. Saltz Another study of how to give fluorouracil? J Clin Oncol 21 2003 3711 3712
5. M.L. Rothenberg N.J. Meropol E.A. Poplin Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel J Clin Oncol 19 2001 3801 3807
6. R.M. Goldberg D.J. Sargent R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
7. M. Koopman N.F. Antonini J. Douma Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 2007 135 142
8. M.T. Seymour T.S. Maughan J.A. Ledermann Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 2007 143 152
9. E. Van Cutsem P.M. Hoff P. Harper Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials Br J Cancer 90 2004 1190 1197
10. Meta-Analysis Group in Cancer Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors J Clin Oncol 16 1998 3537 3541
11. Meta-Analysis Group in Cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 1998 301 308
12. M.A. Poon M.J. O'Connell C.G. Moertel Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma J Clin Oncol 7 1989 1407 1418
13. Nordic Gastrointestinal Tumor Adjuvant Therapy Group Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer Ann Oncol 4 1993 235 241
14. B. Glimelius A. Jacobsen W. Graf Bolus injection (2–4 minutes) versus short-term (10–20 minutes) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomized trial Eur J Cancer 34 1998 674 678
15. A. Jakobsen Å Berglund B. Glimelius Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer Acta Oncol 41 2002 525 531
16. B. Glimelius R. Ristamaki M. Kjaer Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer Ann Oncol 13 2002 1868 1873
17. H. Sørbye B. Glimelius Å Berglund Multicentre phase II study of Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (FLOX) as first-line treatment of metastatic colorectal cancer J Clin Oncol 22 2004 31 38
18. P. Therasse S.G. Arbuck E.A. Eisenhauer New guidelines to evaluate response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
19. A. deGramont J.F. Bosset C. Milan Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study J Clin Oncol 15 1997 808 815
20. National Cancer InstituteNational Cancer Institute Common Toxicity Criteria. http://ctep.cancer.gov/reporting/ctc.html
21. C.D. Blanke Whither irinotecan? J Clin Oncol 23 2005 4811 4814
22. N.J. Meropol Turning point for colorectal cancer clinical trials J Clin Oncol 24 2006 3322 3324
23. R.M. Goldberg D.J. Sargent R.F. Morton Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial J Clin Oncol 24 2006 3347 3353
24. J.A. Meyerhardt R.J. Mayer Systemic therapy for colorectal cancer N Engl J Med 352 2005 476 487
25. C.S. Fuchs J. Marshall E.P. Mitchell Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations ± celecoxib in mCRC: clinical data cut-off September 1, 2006 2007 Proc Am Soc Clin Oncol (Abstr 276)
26. C. Köhne J. de Greve C. Bokemeyer Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015. Proc Am Soc Clin Oncol 2005 (Abstr 3525)
27. W. Graf B. Glimelius L. Påhlman R. Bergström The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer Br J Cancer 70 1994 559 563
28. T. Andre C. Boni L. Mounedji-Boudiaf Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351
29. E. Mitry C. Tournigand T. Andre Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer–a pooled analysis of 254 patients included in 2 randomised trials Proc Am Soc Clin Oncol 2004 (Abstr 3576)
30. C. Tournigand T. Andre E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
31. A.F. Sobrero C. Aschele J.R. Bertino Fluorouracil in colorectal cancer–a tale of two drugs: implications for biochemical modulation J Clin Oncol 15 1997 368 381